悦康药业(688658.SH)子公司YKYY018雾化吸入剂治疗与预防人副流感病毒感染的适应症获FDA临床试验批准

智通财经
Nov 12

智通财经APP讯,悦康药业(688658.SH)发布公告,公司子公司北京悦康科创医药科技股份有限公司(简称“悦康科创”)于近日获得了美国食品药品监督管理局(简称“FDA”)关于同意YKYY018雾化吸入剂用于人副流感病毒感染治疗与预防的临床试验申请的函告。

目前,YKYY018雾化吸入剂针对RSV感染的临床ⅠI期临床研究正在稳步推进中。本次该候选药物治疗与预防HPIV感染的临床试验申请获FDA许可开展,是继RSV和hMPV相关临床试验申请获批后的又一重要进展,进一步拓展了YKYY018雾化吸入剂在呼吸道病毒感染防治领域的临床开发布局,为未来满足多种呼吸道病毒感染的临床治疗需求奠定了基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10